Carol Ann Satler
Senior Vice President, Global Clinical Development Insilico Medicine
Dr. Carol Ann Satler is a physician executive with 20+ years of experience leading global clinical development across top pharma and biotech companies including Pfizer, Sanofi, Takeda, Gilead, PureTech and the generative AI company, Insilico Medicine. She has overseen programs from discovery through commercialization, including multi-billion-dollar launches such as Plavix and Lipitor. Former President and CMO of Respira Therapeutics, she excels at translating scientific innovation into improved patient outcomes. A board-certified pediatric cardiologist and Harvard faculty alumna, she holds an MD-PhD from Case Western and has served on boards including the American Heart Association, Carbon Biosciences, and Vicardia Therapeutics.
Seminars
- Revisiting TNIK inhibition as a therapeutic strategy in IPF and reflecting on how AI-enabled discovery has progressed from candidate identification to multi-program clinical advancement
- Updates on Phase 2b progression in the US, Phase 3 initiation in China, and the strategic considerations behind multinational late-stage expansion
- Advancing an inhaled IPF programme into Phase 1 and discussing how formulation strategy, delivery route, and lifecycle planning may shape future positioning in an increasingly competitive IPF landscape
